ArticleHuman mutation2026
CENPA as a Genome Stability-Associated Biomarker in Hepatocellular Carcinoma: Multiomics Analysis and Experimental Validation.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genomic instability is closely involved in hepatocellular carcinoma (HCC) progression, but biomarkers that reflect genome stability-related tumor biology and functional vulnerability remain incompletely defined. In this study, we performed an integrative multiomics analysis to identify genome stability-associated candidates in HCC and experimentally evaluated the functional relevance of CENPA. By intersecting genome stability-related genes with differentially expressed and survival-associated genes in TCGA-LIHC, we identified a candidate gene set enriched in mitotic regulation, DNA maintenance, and cell-cycle pathways. A LASSO Cox model was then constructed to derive a 10-gene prognostic signature. Among these genes, CENPA was selected for focused analysis because of its contribution to the model and its established role in centromere identity and chromosome segregation. CENPA was significantly upregulated in HCC tissues, associated with advanced clinicopathological features, and correlated with unfavorable survival outcomes. Copy-number and cell-cycle analyses further linked high CENPA expression to proliferative and genome instability-related molecular states. Functional-state scoring showed strong associations between CENPA expression and cell-cycle activity, DNA repair, and DNA damage-related programs. In vitro, CENPA knockdown suppressed HCC cell proliferation, clonogenic growth, and migration. Moreover, CENPA depletion increased cisplatin sensitivity, reduced IC50 values, and induced G2/M accumulation in HCC cell line models. Collectively, these findings suggest that CENPA is a genome stability-associated biomarker and functional contributor to malignant phenotypes in HCC. The cisplatin-related results further indicate a potential association between CENPA-dependent mitotic regulation and genotoxic stress response, although in vivo and clinical validation are required to determine its translational significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.